Mesenchymal Stem Cell Exosomes Break the Inflammatory Chain of Dry Eye Disease via Multi-Immune Modulation and Ubiquitin Pathways
Background
Dry eye disease (DED) is not merely a simple lack of tears, but a chronic inflammatory disease characterized by the destruction of the tear film, corneal damage, and the collapse of immune balance. Patients suffer from severe ocular pain, foreign body sensations, and blurred vision, experiencing profound fatigue in their daily lives. The prevalence is rising sharply due to increased use of electronic devices and an aging population.
However, existing clinical responses have been limited to artificial tears, steroids, or immunosuppressants. These symptomatic therapies were insufficient to fundamentally block the inflammatory cascade occurring sequentially on the ocular surface. In particular, long-term steroid use carries the risk of side effects such as increased intraocular pressure or cataract formation. Immunosuppressants have also been identified as causes of low patient compliance due to severe burning sensations upon instillation and the months required for therapeutic effects to manifest. This has created an urgent need for new bioactive substances that can normalize the ocular surface microenvironment and induce damaged tissue regeneration.
Key Findings
Mesenchymal stem cell-derived exosomes (MSC-Exos) are considered next-generation therapeutic materials due to their inherently low immunogenicity and tissue regeneration capabilities. A recently published mechanistic analysis study specifically demonstrated that MSC-Exos suppress ocular surface inflammation by simultaneously controlling multiple complex signaling pathways.
The most prominent effect is observed in the comprehensive blockade of inflammatory signaling pathways. The structure strongly inhibits the Toll-like receptor 4 and nuclear factor kappa B (TLR4/NF-κB) signaling axis, which triggers inflammatory responses on the cell surface, while simultaneously blocking the downstream IRAK1/TRAF6/NF-κB cascade. The STAT3 transcriptional regulatory network, which induces inflammatory cytokine production, is also a target of inhibition. The activation pathway of the NLRP3 inflammasome, a key mediator of cell damage and inflammation amplification, was also blocked.
Mechanisms for restoring the balance of immune cells on the lacrimal gland and corneal surface were also revealed. Researchers explain that MSC-Exos produce a synergistic effect by correcting the balance between helper T cells 17 (Th17) and regulatory T cells (Treg) via the gut-eye axis. This method reduces overly aggressive Th17 cells and promotes the proliferation of immune-suppressing Treg cells. Additionally, a mechanism that promotes the FBXW7-mediated ubiquitination pathway, which is a regulator of protein degradation, contributes to accelerating the degradation of inflammatory mediator proteins. In essence, the improvement of the local microenvironment and systemic immune regulation pathways work together organically.
Significance and Outlook
These research results provide clear molecular biological coordinates for the development of next-generation biotherapeutics targeting ocular surface diseases. Unlike existing synthetic drugs that are limited to single receptor blockade, exosomes, as intercellular messengers, organically control multiple signaling networks. If formulated as eye drops or biomaterial composites, they are expected to become a practical therapeutic alternative for severe patient groups unresponsive to existing immunosuppressive therapies.
There are significant engineering and clinical barriers to overcome before commercialization. Overcoming the inherent heterogeneity of exosomes, where the composition of secreted substances varies depending on cell origin and culture conditions, is a primary task. Standardization of separation and purification processes must follow to maintain uniform quality during mass production. Due to the nature of the eye, where drugs are rapidly washed away by blinking and tear circulation, increasing drug delivery efficiency and in vivo persistence is also a difficult challenge. Researchers point to the convergence of nanotechnology and gene-editing technology as the solution. When engineered exosomes, with amplified therapeutic functions through surface modification or genetic engineering, are developed, the era of precision biologics for dry eye disease is expected to officially begin.
Dry eye disease (DED) is a chronic ocular surface disorder triggered by tear film imbalance, in which inflammatory disruption of immune homeostasis constitutes the core pathological mechanism. Mesenchymal stem cell-derived exosomes (MSC-Exos) offer promising anti-inflammatory therapeutic potential through immune modulation, tissue repair, and their inherently low immunogenicity. This review elucidates MSC-Exos' molecular regulation of DED inflammation, demonstrating their suppression of the TLR4/NF-κB signaling axis, the IRAK1/TRAF6/NF-κB cascade reaction, the STAT3 transcriptional regulatory network, and the NLRP3 inflammasome activation pathway, while revealing a synergistic mechanism through which MSC-Exos ameliorate the ocular surface inflammatory microenvironment by modulating Th17/Treg immune balance via the gut-eye axis and facilitating FBXW7-mediated ubiquitination degradation pathways. Despite this therapeutic potential, clinical translation is hampered by exosomal heterogeneity, difficulties in standardization, and suboptimal delivery efficiency and long-term efficacy. Future progress will require the integration of nanotechnology and gene editing to enhance therapeutic functionality, ultimately positioning MSC-Exos as precision biologics for DED.
In clinical ophthalmology, the treatment protocol for dry eye disease will shift from short-term symptom relief to the fundamental reconstruction of the immune microenvironment. Patients who had previously relied on frequent artificial tear instillation or endured the burning sensation associated with immunosuppressant therapy can reduce their treatment burden through high-efficiency exosome eye drop therapy. This marks a direct turning point for preserving vision and improving the quality of life in severe patients at risk of chronic corneal damage and ulcers.
For the pharmaceutical and biotech industries, this provides a technological turning point to standardize the previously vague efficacy of stem cell therapies into precise data at the nanovesicle level. In particular, joint development is expected to become more active with companies that possess nano-carrier synthesis technology or cell-line gene-editing platforms. The exosome pipeline for dry eye disease treatment has a high potential to expand its indications to ocular surface complications resulting from Sjögren's syndrome or graft-versus-host disease.